Last updated: September 30, 2026
Allergan USA, Inc. sued MSN Laboratories Private Limited in the District of Delaware over MSN’s abbreviated new drug application for generic Vraylar, the cariprazine product marketed by Allergan and AbbVie. The case centered on U.S. Patent No. 9,056,137 and the application of obviousness-type double patenting to related cariprazine patents. The Federal Circuit later reversed the district court’s invalidity ruling, holding that a first-filed, first-issued patent cannot be invalidated for obviousness-type double patenting over a later-filed, later-issued patent claiming the same invention priority framework.[1]
The litigation has major commercial significance because Vraylar generated more than $3 billion in U.S. sales in 2023 and remains one of the highest-value atypical antipsychotic products facing generic entry.[2]
What is Allergan USA v. MSN Laboratories?
The case is a Hatch-Waxman patent infringement action filed in the U.S. District Court for the District of Delaware:
| Item |
Information |
| Case |
Allergan USA, Inc. v. MSN Laboratories Private Limited |
| Civil action |
No. 1:19-cv-01727-RGA |
| Court |
U.S. District Court for the District of Delaware |
| Judge |
Richard G. Andrews |
| Plaintiff |
Allergan USA, Inc. |
| Defendant |
MSN Laboratories Private Limited |
| Product |
Generic cariprazine capsules |
| Reference product |
Vraylar |
| Regulatory pathway |
Abbreviated New Drug Application |
| Core patent |
U.S. Patent No. 9,056,137 |
| Federal Circuit appeal |
Allergan USA, Inc. v. MSN Laboratories Private Ltd., No. 24-1061 |
MSN filed an ANDA seeking approval to market generic cariprazine capsules in strengths corresponding to Vraylar. Allergan alleged that the ANDA filing infringed claims of the ’137 patent under 35 U.S.C. § 271(e)(2).
What drug and formulation were at issue?
Vraylar contains cariprazine hydrochloride, an atypical antipsychotic used to treat schizophrenia and bipolar disorder. The FDA approved Vraylar in 2015 for schizophrenia and manic or mixed episodes associated with bipolar I disorder. FDA later expanded the label to include depressive episodes associated with bipolar I disorder and adjunctive treatment of major depressive disorder.[3]
The commercial product is an oral capsule. The relevant patent estate includes claims directed to cariprazine compounds, pharmaceutical compositions, dosage forms, and therapeutic uses. The ’137 patent was particularly important because it covered the active pharmaceutical ingredient and related pharmaceutical compositions in a manner that Allergan asserted against generic ANDA applicants.
What patents protect Vraylar?
Vraylar has been protected by a portfolio rather than by a single patent. The principal categories are:
| Patent category |
Commercial function |
Relevance to MSN litigation |
| Compound patents |
Protect cariprazine and related chemical structures |
Establish core molecule protection |
| Composition patents |
Cover pharmaceutical compositions containing cariprazine |
Support infringement claims against capsule products |
| Formulation patents |
Address dosage-form or stability characteristics |
Can delay generic entry if listed and enforceable |
| Method-of-use patents |
Cover treatment of schizophrenia, bipolar disorder, or depression |
May support partial or skinny-label litigation |
| Patent-term-adjusted patents |
Extend effective patent protection beyond ordinary expiration |
Increase the value of the Orange Book estate |
The principal patent dispute in the MSN case involved the ’137 patent and whether its claims were unpatentable for obviousness-type double patenting over a later-issued related patent. The dispute was not limited to whether MSN’s product contained cariprazine. It also concerned the legal effect of related patent prosecution, priority claims, patent-term adjustment, and continuation practice.
What was U.S. Patent No. 9,056,137?
U.S. Patent No. 9,056,137 issued on June 16, 2015. Allergan asserted the patent against MSN’s ANDA filing. The patent is associated with cariprazine pharmaceutical compositions and related subject matter.
The patent’s importance arose from its position within a family of related applications. The Federal Circuit described the dispute as involving a first-filed, first-issued patent challenged for obviousness-type double patenting over a later-filed, later-issued patent. The court rejected the proposition that the later patent could be used to invalidate the earlier patent merely because both patents shared an overlapping priority structure.[1]
What did the district court decide?
The district court determined that the asserted claims of the ’137 patent were invalid under the doctrine of obviousness-type double patenting. The ruling treated a later-issued related patent as a proper reference for the double-patenting analysis.
Obviousness-type double patenting is a judicially created doctrine that prevents an applicant from obtaining an unjustified second patent covering an obvious variation of an earlier patented invention. The doctrine is intended to prevent patent-term extension through serial patenting. It is distinct from statutory obviousness under 35 U.S.C. § 103.
The district court’s analysis created a critical problem for Allergan. If the ’137 patent were invalid, Allergan would lose the principal patent asserted against MSN’s ANDA, subject to appeal and the status of other Orange Book-listed patents.
How did the Federal Circuit rule?
The Federal Circuit reversed the district court’s invalidity determination.[1]
The appellate court held that a first-filed, first-issued patent cannot be invalidated for obviousness-type double patenting over a later-filed, later-issued patent when the patents share the relevant priority relationship. The court’s reasoning limited the ability of a later patent to serve as an obviousness-type double-patenting reference against an earlier patent.
The decision has broader consequences for pharmaceutical patent families. It reduces the risk that later-issued continuation or divisional patents can be used to attack an earlier-issued patent solely because the later patent contains overlapping claims or receives a longer patent term.
Federal Circuit holding
| Issue |
Federal Circuit result |
| Use of later-issued patent as an obviousness-type double-patenting reference |
Rejected in the circumstances presented |
| Validity of the ’137 patent under the district court’s ODP theory |
District court ruling reversed |
| First-filed, first-issued patent |
Protected against this form of later-patent ODP attack |
| Case posture |
Remanded for further proceedings consistent with the opinion |
The appellate ruling did not automatically authorize MSN to launch. ANDA approval, the status of other patents, any applicable judgment terms, and the scope of the final remand remained relevant to commercial entry.
What was MSN’s Paragraph IV position?
MSN’s ANDA filing operated as a Paragraph IV challenge to Allergan’s listed patent rights. Under the Hatch-Waxman Act, a generic applicant may certify that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.
A Paragraph IV certification is treated as an artificial act of infringement under § 271(e)(2). The branded company may file suit within 45 days of receiving notice. A timely suit generally triggers a 30-month stay of FDA approval, subject to statutory exceptions and court action.
The litigation therefore functioned as both:
- A patent-validity dispute over the ’137 patent; and
- A regulatory timing mechanism that could postpone FDA approval of MSN’s ANDA.
The public record does not establish that the Federal Circuit decision alone resulted in immediate generic launch. A court victory on one patent does not eliminate separate patents, regulatory holds, settlement terms, or other barriers.
What is the Orange Book status of Vraylar?
FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, identifies patents and regulatory exclusivity associated with approved drug products. Vraylar’s patent listings have included patents directed to cariprazine and related product or use claims.[4]
Orange Book status must be analyzed patent by patent. A listed patent can affect ANDA approval even if another patent in the same family has been invalidated or narrowed. A generic applicant may also use a Paragraph IV certification, a Paragraph III certification, a section viii statement for method-of-use patents, or a certification that the patent is no longer relevant.
For Vraylar, the most important legal distinction is between:
- Core product protection for cariprazine;
- Formulation and composition protection;
- Method-of-use patents;
- Patent-term-adjusted expiration dates; and
- Unlisted or non-Orange-Book intellectual property that may still affect manufacturing or commercial risk.
When does Vraylar lose exclusivity?
Vraylar’s exclusivity does not have one universal end date. The practical loss of exclusivity depends on several dates:
| Exclusivity factor |
Effect |
| New chemical entity exclusivity |
Blocks ANDA approval for the statutory period after initial approval |
| Listed patent expiration |
Determines when FDA may approve an ANDA subject to that patent |
| Patent-term adjustment |
Can extend expiration beyond the nominal 20-year term |
| Pediatric exclusivity |
Can add six months to qualifying regulatory exclusivities and patent periods |
| Litigation stay |
Can delay approval during Hatch-Waxman litigation |
| Settlement terms |
May permit an agreed launch date before or after patent expiration |
| Other listed patents |
Can preserve a later approval barrier after one patent falls |
Vraylar received FDA approval in 2015, placing the ordinary five-year new chemical entity exclusivity period in 2020. That regulatory exclusivity did not itself determine market entry because patent litigation and listed patents remained relevant after the NCE period ended.[3]
Public patent databases identify Vraylar-related patent rights extending into the 2030s, depending on the specific patent, patent-term adjustment, and indication. The ’137 patent was issued in 2015 and became the subject of the ODP dispute in this action. Its litigation status cannot be used as a substitute for a complete Orange Book review of every listed patent.
What patent litigation affects generic cariprazine?
Vraylar has faced multiple generic challenges because cariprazine is a high-value product with broad psychiatric indications. The competitive litigation environment has included ANDA filers seeking approval for capsule products and branded-company suits directed to listed patents.
The MSN case is significant because it addressed the architecture of the patent family, not only the chemistry or formulation of the generic product. The Federal Circuit’s ruling affects how branded companies and generic applicants evaluate:
- Continuation and divisional patent strategy;
- Patent-term adjustment;
- Double-patenting risk;
- Priority-date sequencing;
- Orange Book listing strategy; and
- Settlement leverage in ANDA litigation.
A generic applicant that defeats one patent may still face a different patent covering a formulation, dosage regimen, or indication. Conversely, a branded company may lose practical leverage if the remaining claims are narrow, easy to design around, or vulnerable to a section viii carveout.
How strong is Allergan’s Vraylar patent estate?
The estate is commercially strong but legally segmented.
Strengths
- Cariprazine is a specialized active ingredient with meaningful formulation and clinical-use complexity.
- The product has multiple approved psychiatric indications.
- Related patent families can create separate validity and infringement issues.
- The Federal Circuit ruling strengthened the position of an earlier-issued patent against the specific ODP theory presented.
- Generic approval remains subject to the combined effect of all relevant patents and regulatory exclusivities.
Weaknesses
- Core composition claims may face validity attacks based on obviousness, written description, enablement, or double patenting.
- Method-of-use patents can be weakened by label carveouts.
- Formulation claims may be vulnerable to non-infringing manufacturing routes or alternative excipients.
- ANDA litigation can expose patent-family inconsistencies and terminal-disclaimer issues.
- Patent protection does not prevent off-label use or automatically block all non-ANDA routes to competition.
The Federal Circuit outcome improved Allergan’s position on the ’137 patent, but it did not establish that every Vraylar-related patent would survive a validity challenge.
What generic entry risks exist for Vraylar?
The principal entry scenarios are:
| Scenario |
Commercial result |
| MSN wins on all remaining barriers |
FDA approval and potential launch before full patent expiry |
| Allergan preserves surviving patents |
Delayed approval or settlement-controlled entry |
| Partial invalidity or non-infringement |
Launch may proceed for some indications or after a negotiated date |
| Section viii carveout |
Generic approval for non-protected indications |
| Settlement |
Entry date determined by agreement, subject to antitrust and regulatory constraints |
| At-risk launch |
Generic launches before final resolution, exposing the company to damages and injunction risk |
An at-risk launch would carry substantial exposure because Vraylar sales are large and the product has a limited number of direct substitutes with the same mechanism and indication mix. A generic entrant would also face price erosion, payer substitution, and possible launch coordination among multiple ANDA filers.
Were there licensing deals or settlement agreements?
No publicly established settlement agreement or license should be treated as controlling MSN’s entry position unless it appears in a filed court document, consent judgment, SEC filing, or other authoritative record.
Patent settlements in pharmaceutical litigation often include:
- A defined generic entry date;
- A license tied to patent expiration;
- Launch rights under specified conditions;
- Restrictions on authorized generic competition;
- Covenants not to sue;
- Acceleration provisions if patents are invalidated; and
- Confidential commercial terms.
The Federal Circuit decision itself was a merits ruling on the ODP issue. It was not a settlement and did not replace the need to examine any separate judgment or agreement governing MSN’s ANDA.
What is the business impact of the case?
Vraylar’s revenue exposure makes the case important for both Allergan and generic competitors. A generic launch could produce rapid U.S. price erosion because pharmacy benefit managers and Medicare plans commonly substitute therapeutically equivalent generics once available.
For Allergan, preserving the ’137 patent supports:
- Continued branded pricing;
- Negotiating leverage with ANDA applicants;
- Protection of high-margin psychiatric sales;
- More favorable settlement economics; and
- Time to shift patients or revenue toward newer products.
For MSN, the Federal Circuit ruling removes one major invalidity basis but does not eliminate all launch risk. MSN must still account for the final scope of the ’137 patent, other Orange Book patents, FDA approval timing, manufacturing readiness, and potential damages exposure.
Key Takeaways
- Allergan sued MSN over its ANDA for generic Vraylar, or cariprazine capsules.
- The central patent was U.S. Patent No. 9,056,137.
- The district court invalidated the asserted claims under obviousness-type double patenting.
- The Federal Circuit reversed, holding that a first-filed, first-issued patent cannot be invalidated over a later-filed, later-issued patent on the theory presented.
- The ruling strengthened Allergan’s position but did not automatically authorize MSN’s launch.
- Vraylar’s exclusivity depends on the combined effect of Orange Book patents, regulatory exclusivity, patent-term adjustment, litigation status, and any settlement.
- Formulation, method-of-use, manufacturing, and geographic issues remain relevant beyond the ’137 patent.
- Generic entry would expose Allergan to substantial U.S. revenue erosion because Vraylar is a multibillion-dollar product.
FAQs About Allergan v. MSN Laboratories and Vraylar Generic Entry
What ANDA did MSN Laboratories file for Vraylar?
MSN filed an ANDA seeking approval for generic cariprazine capsules corresponding to Vraylar. The ANDA triggered Allergan’s Hatch-Waxman infringement action after MSN served Paragraph IV notice.
Did MSN win the Allergan Vraylar patent case?
MSN prevailed in the district court on the ODP invalidity theory, but the Federal Circuit reversed that ruling. The appellate decision therefore restored Allergan’s position on the challenged patent issue.
Does the Federal Circuit decision mean generic cariprazine can launch immediately?
No. Launch depends on the complete patent and regulatory record, including other listed patents, the final remand, FDA approval, and any settlement or judgment terms.
Does the case affect biosimilar competition?
No. Cariprazine is a small-molecule drug, so the relevant competitive pathway is an ANDA for a generic drug, not a biosimilar application under the Biologics Price Competition and Innovation Act.
Can a generic carve out Vraylar’s patented indications?
Potentially. If a listed patent covers only a method of use, an ANDA applicant may seek approval with a section viii statement and omit the protected indication, subject to the product label and infringement analysis.
References
- U.S. Court of Appeals for the Federal Circuit. (2025). Allergan USA, Inc. v. MSN Laboratories Private Ltd., No. 24-1061.
- AbbVie Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023.
- U.S. Food and Drug Administration. (2015-present). Vraylar: Drugs@FDA prescribing information and approval history.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- U.S. District Court for the District of Delaware. (2019-present). Allergan USA, Inc. v. MSN Laboratories Private Limited, No. 1:19-cv-01727-RGA.
